Drugs / Estrogens, Conjugated (USP)
Estrogens, Conjugated (USP)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00083824 | Mar 2004 → Feb 2007 | coronary atherosclerosis | Tufts University | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT01482416 | Nov 2011 → Aug 2014 | — | Federal University of Minas Gerais | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Estrogens, Conjugated (USP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083824 ↗ |
| Known as | CEE | “Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 20081“the use of conjugated equine estrogens (CEE) or placebo” PMID 27427235 ↗ Jul 2016 |
| Known as | conjugated equine estrogen | “Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 2008 |
| Known as | conjugated equine estrogens | “the use of conjugated equine estrogens (CEE) or placebo” PMID 27427235 ↗ Jul 2016 |